| INTRODUCTION
Prostate cancer (PCa) is the most commonly diagnosed malignancy and the second leading cause of cancer death in American males. In 2018, it was estimated there would be 164 690 new prostate cancer cases and 29 430 deaths due to prostate cancer. 1 Androgen receptor (AR) plays a central role in normal prostate development as well as the development and progression of prostate cancer, [2] [3] [4] and androgen deprivation therapy (ADT) remains the standard treatment for patients with metastatic prostate cancer. 5 Unfortunately, despite an initial significant clinical response to ADT, most patients relapse with lethal castration-resistant prostate cancer (CRPC) after a mean time of 2-3 years. 6 AR activation under androgen depleted condition is the major mechanism driving CRPC development. 7, 8 Therefore, highly potent second generation AR signaling targeting agents including abiraterone acetate and enzalutamide have been developed to inhibit AR signaling in CRPC. [9] [10] [11] However, both initial and acquired resistance to the second-generation AR targeting agents are common, which leads to prostate cancer mortality. Understanding mechanisms of this resistance is of great clinical significance.
According to studies by multiple investigators, the resistance mechanisms can be stratified into "AR-dependent" and "AR-independent" mechanisms. [12] [13] [14] AR-independent resistance mechanisms include glucocorticoid receptor overexpression, neuroendocrine differentiation, and immune system deregulation. [15] [16] [17] [18] AR-dependent resistant mechanisms are the major mechanisms and include AR amplification, hyperactivation, mutation, expression of constitutively active AR splice variants, abnormalities in AR co-factors, DNA methylation of promoter, and intratumoral androgen biosynthesis. 12, [19] [20] [21] [22] [23] Novel approaches to inhibit AR signaling in prostate cancer cells may result in new therapeutics for CRPC.
Through a yeast mutagenesis screen, we found PRP43 as a potential factor regulating AR subcellular localization and function. 24 The mammalian ortholog of Prp43 is DHX15, a member of the DEAH-box (DHX) RNA helicase family that can regulate a lot of biological processes, including RNA metabolism, cellular differentiation and apoptosis. 25 Dysregulation of RNA helicase family proteins is commonly observed in tumor initiation and development. 26, 27 However, specific functions of individual members of RNA helicase family remain elusive. DHX15 was reported to act as a tumor suppressor in glioma, 28 participate in immune response, 29 regulate intestinal antiviral innate immunity through activation of the Nlrp6-interferon pathway, 30 and inhibit the migration and proliferation of gastric cancer. 31 These findings suggest that DHX15
can have diverse functions in different types of cells. We recently reported that DHX15 can act as a novel AR coactivator in prostate cancer cells. 24 In our study, DHX15 could stabilize Siah2 levels and enhance its E3 ubiquitin ligase activity, subsequently resulting in the activation of AR. In hormone naïve prostate cancer specimens, DHX15
was upregulated and its expression was correlated with Gleason score and prostate-specific antigen (PSA) recurrence, suggesting that DHX15
could potentially contribute to the progression prostate cancer. 24 However, the role of DHX15 in prostate cancer, particularly in CRPC, remains to be fully elucidated. In the present study, we evaluated DHX15 expression in CRPC specimens and explored DHX15 regulation of AR signaling in the CRPC cell line C4-2, potential DHX15 modulation of enzalutamide resistance, and physical interaction between DHX15
and AR.
| MATERIALS AND METHODS

| Plasmid constructs
Full-length or part of DHX15 coding region was amplified by PCR using Myc-DHX15 as template and then cloned into the SacI and KpnI sites of pEGFP-C1 to construct GFP tagged GFP-DHX15, GFP-DHX15
[amino acids (aa) 1-475] and GFP-DHX15 (aa 476-795). Then GFP-DHX15 (aa 1-322) and GFP-DHX15 (aa 323-475) were generated from GFP-DHX15 (aa 1-475) by deletion mutagenesis using Q5 ® SiteDirected Mutagenesis Kit (E0554S, New England Biolabs) according to the manufacture's protocol. Similarly, GFP-DHX15 (aa 476-661) and GFP-DHX15 (aa 629-795) were generated from GFP-DHX15 (aa 476-795). All constructed plasmids were sequence confirmed. Enzalutamide-resistant 22Rv1 cells (Enz R -22Rv1) were generated by culturing 22Rv1 cells in complete RPMI-1640 media in the presence of 10 μM enzalutamide for several months (as described previously 33 ).
| Cell culture
Once cells became resistant, they were maintained in complete RPMI- 
| Colony formation assay
Cells (1 × 10 3 or 2 × 10 3 ) were seeded into 6-well plates with medium containing 0-100 nM DHT or 0-10 μM MDV3100 as indicated. The colonies formed 8-15 days later were stained with 0.5% crystal violet, and colonies with a diameter equal to or larger than 0.5 mm were counted by ImageJ software (NIH, USA). Each cell growth and colony formation assay was carried out in triplicate and repeated three times. and total cell lysates were boiled in SDS loading buffer for 10 min and then subjected to Western blot analysis using anti-GFP antibody (TP401, Chemokine and MA1-952, Thermofisher Scientific) and anti-AR antibody (sc-816, Santa Cruz).
| Co-immunoprecipitation
| Immunohistochemistry and tissue microarray analysis (TMA)
The TMAs containing CRPC specimens were obtained from Prostate
Cancer Biorepository Network (PCBN) and Duke University (Dr. Jiaoti Huang). Use of these prostate tissues was approved by the PCBN and the University of Pittsburgh Institutional Review Board. Immunohistochemical staining was performed on the paraffin embedded TMA using DHX15 antibodies (sc-271686, (E-6), Santa Cruz Biotechnologies) as described previously. 34 DHX15 expression was assessed as a function of staining intensity and percentage of cells exhibiting each level of intensity, as previously. 34 The intensity of the reaction product was based on a 4-point scale: none, faint/equivocal, moderate, and
intense. An H-score was calculated using the following formula: Hscore = 0(% no stain) + 1(% faint/equivocal) + 2(% moderate) + 3(% intense).TMAs were scored by three investigators in a blinded fashion (YDX, FMD, LEP).
| Statistical analysis
All graphs were generated using GraphPad Prism 6 software (GraphPad Software, Inc. La Jolla, CA). The data are presented as mean ± SEM.
Statistical analyses were performed with Student's t-test. P < 0.05 was considered statistically significant.
| RESULTS
| DHX15 expression was upregulated in CRPC specimens
To evaluate the potential role of DHX15 in CRPC, we performed showed a nuclear expression pattern in both hormone naïve and CRPC specimens ( Figure 1A ). DHX15 expression was upregulated in CRPC samples compared to hormone naïve tumor samples (P = 0.0126) ( Figure 1B ).
| DHX15 knockdown reduced AR sensitivity to low DHT concentrations in C4-2 cells
As an AR co-factor, DHX15 may sensitize the responsiveness of AR to androgens. The C4-2 cell line was reported to exhibit hypersensitivity to DHT, 35, 36 providing an excellent model to test the effect of DHX15 knockdown on AR activity at low DHT concentrations. Following siDHX15 knockdown, C4-2 cells were cultured in charcoal-stripped medium containing DHT at concentrations ranging from 0 to 100 nM and the expression pattern of three AR target genes, ELL2, EAF2, and PSA, was determined. We did not treat cells with DHT at concentrations higher than 100 nM, because 100 nM is already much higher than physiological level of DHT (0.38-3.27 nM). 37 In the presence of control siRNA, the maximal expression of androgen-response genes was induced at 1 nM DHT for EAF2 or 10 nM DHT for ELL2 and PSA (Figure 2A ). In the presence of siRNA targeting DHX15, the maximal induction of androgen-response genes was observed when the cells were cultured in the presence of 100 nM DHT (Figure 2A ). This observation suggested that DHX15 knockdown caused a shift of the DHT concentration required for stimulating maximal expression of androgen-response gene expression from 1 to 10 nM to 100 nM or greater. To exclude the off-target effect of siRNA targeting DHX15, we also inhibited DHX15 expression using another siRNA targeting DHX15 and observed a similar result ( Figure 2B ).
We also measured the colony formation for C4-2 cells in response to various DHT concentrations with or without DHX15 knockdown ( Figure 3A) . Quantification of C4-2 colonies resulted in a bell-shaped growth in response to increasing DHT concentrations ( Figure 3B ). This result was consistent with the bell-shaped growth curve in response to increasing DHT concentrations in the LNCaP model. [38] [39] [40] The bellshaped growth curves were observed in the presence of either control siRNA or siRNA targeting DHX15 ( Figure 3B ). However, DHX15
knockdown inhibited C4-2 cell growth when DHT concentrations were at 0.1 nM or lower but not at 1 nM or higher DHT concentrations.
This result suggests that DHX15 is important for C4-2 cells growth in the presence of castrate levels of androgens. 
| DHX15 knockdown enhanced the sensitivity of C4-2 cells to enzalutamide (MDV3100)
AR co-regulators have been postulated as potential drivers of enzalutamide resistance in prostate cancer cells. 41 Since DHX15
was identified as an AR coactivator, 24 it may play a role in enzalutamide resistance in prostate cancer cells. Thus, we tested if DHX15 knockdown could enhance the sensitivity of prostate cancer cells to enzalutamide using C4-2 as a model, since C4-2 is a CRPC cell line derived from LNCaP. 42, 43 After DHX15 knockdown, C4-2 cells were subjected to colony formation assay in the presence of enzalutamide Figure S1B ). The sensitivity of 22Rv1 to enzalutamide in culture was not affected by DHX15 knockdown ( Figure 4D ). We also tested the effect of DHX15 knockdown on enzalutamide sensitivity in knockdown (Supplemental Figure S2) . We also performed the same assay in two AR-negative prostate cancer cell lines, PC3 and DU145.
As expected, enzalutamide had no significant effect on proliferation of these two cell lines in the presence siNC or siDHX15 ( Figure 4E and H, Supplemental Figure S1C , D).
| AR co-immunoprecipitates with the N-terminal region of DHX15
Our previous results showed that DHX15 co-immunoprecipitated with AR and can regulate AR transcriptional activity. 24 
| DISCUSSION
Our results suggest that DHX15 may play an important role in prostate cancer progression to castration resistance. DHX15 immunostaining appeared to be up-regulated in human CRPC specimens compared to hormone naïve specimens. In a CRPC prostate cancer cell line model, DHX15 knockdown reduced AR sensitivity to DHT and inhibited cell DHX15 appears to be more important for CRPC cell growth when DHT concentrations are low. Our studies showed that DHX15 knockdown reduced C4-2 cell growth when DHT levels were at 0.1 nM or lower but not when DHT level was at 1 nM or higher. Low DHT levels can be stimulatory to prostate cancer cell growth whereas supraphysiological DHT levels are often growth suppressive. 38, 40 Since DHX15 appears to be an AR co-activator, DHX15 knockdown should reduce the efficacy of androgens to stimulate AR. As expected, when DHT levels were ≤0.1 nM, DHX15 knockdown reduced the growth stimulatory effect of DHT in C4-2 cells. Similarly, when DHT levels were 1 nM or above, DHX15 knockdown reduced the growth Supraphysiological androgen suppression of CRPC was observed and represents a potential treatment for CRPC patients. [44] [45] [46] [47] [48] However, it is not clear why supraphysiological androgen therapy is only effective in some CRPC patients. The AR transcriptional activity and growth showed bell-shape curves in response to increasing DHT concentrations in C4-2 provides a potential model for studying supraphysiological suppression of CRPC. The expression levels of AR target genes increased along with the increasing level of DHT at first, and then decreased at supraphysiological DHT concentrations.
However, the suppression of androgen-response gene expression by high levels of DHT was not observed when DHX15 was knocked down. Also, the growth suppression of C4-2 by high DHT was partially alleviated by DHX15 knockdown. This suggests that CRPC with low DHX15 may be less sensitive to supraphysiological DHT suppression.
Future studies will be needed to address the potential role of DHX15 in supraphysiological androgen suppression of prostate cancer.
The effect of DHX15 knockdown to sensitize cells to enzalutamide appears to be mediated through AR, particularly the LBD domain that binds to DHX15. 24 Although DHX15 knockdown could inhibit the growth of AR-negative DU145 and PC3 cells in colony formation assay, the sensitivity of these AR-negative cells to enzalutamide was not affected by DHX15 knockdown. Also, DHX15 knockdown did not influence the effect of enzalutamide on both parental and enzalutamide-resistant 22Rv1 cells, which express both full-length AR and AR splice variants lacking LBD. The AR splice variants are thought to drive enzalutamide resistance in 22Rv1 cells because these AR variants do not respond to enzalutamide that targets LBD. In our previous studies, we reported that DHX15 interact with LBD of AR. 24 Therefore, DHX15 knockdown should not affect AR splice variants and Using colony formation assay, here we showed that DHX15 knockdown could also inhibit cell growth in AR-negative cells (Supplemental Figure S3 ). This finding is not surprising, considering that DHX15 is a component of splicesome and involved in RNA splicing. Ito S, et al. reported that DHX15 acted as a tumor suppressor in glioma 28 ; Xiao YF, et al., discovered its role in the inhibition of migration and proliferation role in gastric cancer. 31 These findings suggest that DHX15 can modulate multiple signaling pathways in addition to AR. However, we previously did not detect inhibition of DU145 and PC3 cells proliferation by DHX15 knockdown using a BrdU assay. 24 One potential reason for the difference is that colony formation assay can detect long-term and cumulative effects of DHX15 knockdown on cell growth and cell death, whereas BrdU assay only detects short-term effects of DHX15 knockdown on DNA synthesis. We compared BrdU and colony formation assay in DU145
and PC3 cells. BrdU assay did not detect the effect of DHX15 knockdown on DU145 (data not shown), which was detected by colony formation assay. Thus, we decided to use colony formation assay in this study. Another possibility that could affect reproducibility is phenotype drifting of cultured cells and we cannot rule out this possibility since the PC3 cells used in our previous studies were not authenticated. To minimize this potential variable, all the cells used in this study were recently purchased or authenticated.
| CONCLUSIONS
In summary, these studies suggested that DHX15 is likely to play an important role in prostate cancer progression to castration resistance via enhancing AR activity. Targeting DHX15 should inhibit AR activity and enhance the efficacy of antiandrogens in CRPC. However, inhibition of DHX15 may have side effects because DHX15 is also involved in other pathways important for cell growth. One potential approach will be to develop small molecules that can specifically disrupt interactions between AR and DHX15. This study showed that AR interacts with the N-terminus of DHX15. Future studies to define interactions between AR and DHX15 may lead to novel approaches to specifically target DHX15-AR interaction in CRPC.
